Currently, the research and development technology for prophylactic human papillomavirus (HPV) vaccines is becoming increasingly mature (related reading: "Current Status of Research and Application of Prophylactic Human Papillomavirus (HPV) Vaccines").
The U.S. FDA issued a final guidance on Bispecific Antibody Development Programs. This final guidance provides recommendations for industry and other parties involved in developing bispecific antibodies, which are antibody-based products that target ...
Cipla announced its partnership with the Premier Medical Corporation for commercialisation of the rapid antigen test kits for COVID-19 in India. The company will commence supply from this week.
Genocea’s therapeutic genital herpes vaccine posted new phase 2b data that support the candidate's "groundbreaking potential" as possibly the first genital herpes treatment advancement in more than 20 years, the biotech's CEO says.